Cargando…

Bispecific Antibody Armed Metabolically Enhanced Headless CAR T Cells

Adoptive T cell therapies for solid tumors is challenging. We generated metabolically enhanced co-activated-T cells by transducing intracellular co-stimulatory (41BB, ICOS or ICOS-27) and CD3ζ T cell receptor signaling domains followed by arming with bispecific antibodies (BiAbs) to produce armed “H...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thakur, Archana, Scholler, John, Kubicka, Ewa, Bliemeister, Edwin T., Schalk, Dana L., June, Carl H., Lum, Lawrence G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8288104/ https://www.ncbi.nlm.nih.gov/pubmed/34290709 http://dx.doi.org/10.3389/fimmu.2021.690437

Ejemplares similares

Bispecific antibody-targeted T-cell therapy for acute myeloid leukemia
por: Kubicka, Ewa, et al.
Publicado: (2022)

Priming of pancreatic cancer cells with bispecific antibody armed activated T cells sensitizes tumors for enhanced chemoresponsiveness
por: Thakur, Archana, et al.
Publicado: (2021)

Ipilimumab augments antitumor activity of bispecific antibody-armed T cells
por: Yano, Hiroshi, et al.
Publicado: (2014)

Targeting and killing of glioblastoma with activated T cells armed with bispecific antibodies
por: Zitron, Ian M, et al.
Publicado: (2013)

Novel anti-CD30/CD3 bispecific antibodies activate human T cells and mediate potent anti-tumor activity
por: Faber, Mary L., et al.
Publicado: (2023)

In Situ immunization by bispecific antibody targeted T cell therapy in breast cancer
por: Thakur, Archana, et al.
Publicado: (2015)

Vaccination with bispecific antibody armed T cells (BATC) in metastatic breast cancer patients and transfer of anti-breast cancer immunity in primed T cells after stem cell transplant: a proof of principle study
por: Thakur, Archana, et al.
Publicado: (2015)

Clinical and immune responses to anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (EGFR BATs) in pancreatic cancer patients
por: Lum, Lawrence G., et al.
Publicado: (2020)

Five advanced pancreatic cancer patients in a Phase I study of anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (BATS)
por: Lum, Lawrence G, et al.
Publicado: (2015)

Targeting GD2-positive Refractory/Resistant Neuroblastoma and Osteosarcoma with Anti- CD3 x Anti-GD2 Bispecific Antibody Armed T cells
por: Yankelevich, Maxim, et al.
Publicado: (2023)

LIGHT enhanced bispecific antibody armed T-cells to treat immunotherapy resistant colon cancer
por: Qiao, Guilin, et al.
Publicado: (2022)

Phase II clinical trial using anti-CD3 × anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) consolidation therapy for HER2 negative (0–2+) metastatic breast cancer
por: Lum, Lawrence G., et al.
Publicado: (2021)

Targeted cancer immunotherapy via combination of designer bispecific antibody and novel gene-engineered T cells
por: Urbanska, Katarzyna, et al.
Publicado: (2014)

Anti-CS1 × Anti-CD3 Bispecific Antibody (BiAb)-Armed Anti-CD3 Activated T Cells (CS1-BATs) Kill CS1(+) Myeloma Cells and Release Type-1 Cytokines
por: Lum, Lawrence G., et al.
Publicado: (2020)

Phase I Study of Anti-CD3 x Anti-Her2 Bispecific Antibody in Metastatic Castrate Resistant Prostate Cancer Patients
por: Vaishampayan, Ulka, et al.
Publicado: (2015)

Potent ex vivo armed T cells using recombinant bispecific antibodies for adoptive immunotherapy with reduced cytokine release
por: Park, Jeong A, et al.
Publicado: (2021)

Bispecific Antibodies: From Research to Clinical Application
por: Ma, Jiabing, et al.
Publicado: (2021)

Immunotherapeutic progress and application of bispecific antibody in cancer
por: Kang, Jingyue, et al.
Publicado: (2022)

Maigret and the headless corpse
por: Simenon, Georges, 1903-1989
Publicado: (1967)

VHH-Based Bispecific Antibodies Targeting Cytokine Production
por: Nosenko, Maxim A., et al.
Publicado: (2017)

Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies
por: Lejeune, Margaux, et al.
Publicado: (2020)

Expanding the Therapeutic Window for CAR T Cell Therapy in Solid Tumors: The Knowns and Unknowns of CAR T Cell Biology
por: Watanabe, Keisuke, et al.
Publicado: (2018)

Fc Engineering for Developing Therapeutic Bispecific Antibodies and Novel Scaffolds
por: Liu, Hongyan, et al.
Publicado: (2017)

Therapeutic Bispecific T-Cell Engager Antibody Targeting the Transferrin Receptor
por: Fu, Mingpeng, et al.
Publicado: (2019)

Current landscape and future directions of bispecific antibodies in cancer immunotherapy
por: Wei, Jing, et al.
Publicado: (2022)

Conduit CAR: Redirecting CAR T-Cell Specificity with A Universal and Adaptable Bispecific Antibody Platform
por: Borrok, M. Jack, et al.
Publicado: (2022)

A Focus on CAR T-Cell Therapy and Bispecific Antibodies in Multiple Myeloma
por: Catamero, Donna, et al.
Publicado: (2022)

Bispecific PSMA antibodies and CAR-T in metastatic castration-resistant prostate cancer
por: Zarrabi, Kevin K., et al.
Publicado: (2023)

Potential Role of CD47-Directed Bispecific Antibodies in Cancer Immunotherapy
por: Yang, Yan, et al.
Publicado: (2021)

Tibiotalocalcaneal arthrodesis with headless compression screws
por: Gong, Ji-Cheng, et al.
Publicado: (2016)

Broad reactivity and enhanced potency of recombinant anti-EGFR × anti-CD3 bispecific antibody-armed activated T cells against solid tumours
por: Huang, Manley T. F., et al.
Publicado: (2022)

Bispecific Antibodies for Diagnostic Applications
por: Parashar, Archana, et al.
Publicado: (2011)

Conventional and Chemically Programmed Asymmetric Bispecific Antibodies Targeting Folate Receptor 1
por: Qi, Junpeng, et al.
Publicado: (2019)

A Bispecific Antibody to Link a TRAIL-Based Antitumor Approach to Immunotherapy
por: Satta, Alessandro, et al.
Publicado: (2019)

Design and selection of optimal ErbB-targeting bispecific antibodies in pancreatic cancer
por: Rabia, Emilia, et al.
Publicado: (2023)

Generation of bispecific antibodies by structure-guided redesign of IgG constant regions
por: Iwasaki, Yordkhwan W., et al.
Publicado: (2023)

Bispecific antibodies targeting CTLA-4: game-changer troopers in cancer immunotherapy
por: Farhangnia, Pooya, et al.
Publicado: (2023)

Bispecific antibody-activated T cells enhance NK cell-mediated antibody-dependent cellular cytotoxicity
por: Wang, Zhaoming, et al.
Publicado: (2021)

EGFR-selective activation of CD27 co-stimulatory signaling by a bispecific antibody enhances anti-tumor activity of T cells
por: Melo, Vinicio, et al.
Publicado: (2023)

A Bispecific Antibody-Based Approach for Targeting Mesothelin in Triple Negative Breast Cancer
por: Del Bano, Joanie, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_r7ssfgcbm10m132eevuvt0vcd9